These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29358194)

  • 1. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin.
    Ong KL; Waters DD; Fayyad R; Vogt L; Melamed S; DeMicco DA; Rye KA; Barter PJ
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29358194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio.
    Okumura S; Sakakibara M; Hayashida R; Jinno Y; Tanaka A; Okada K; Hayashi M; Ishii H; Murohara T
    Heart Vessels; 2014 Jan; 29(1):7-14. PubMed ID: 23358876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1131-9. PubMed ID: 17942759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes.
    Muñoz-Hernandez L; Ortiz-Bautista RJ; Brito-Córdova G; Lozano-Arvizu F; Saucedo S; Pérez-Méndez O; Zentella-Dehesa A; Dauteuille C; Lhomme M; Lesnik P; Chapman MJ; Kontush A; Aguilar Salinas CA
    Atherosclerosis; 2018 Oct; 277():72-79. PubMed ID: 30176567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
    Barter P; Gotto AM; LaRosa JC; Maroni J; Szarek M; Grundy SM; Kastelein JJ; Bittner V; Fruchart JC;
    N Engl J Med; 2007 Sep; 357(13):1301-10. PubMed ID: 17898099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.
    Deedwania PC; Stone PH; Fayyad RS; Laskey RE; Wilson DJ
    Drugs Aging; 2015 Dec; 32(12):1055-65. PubMed ID: 26625880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials.
    Idzerda NMA; Pena MJ; Parving HH; de Zeeuw D; Heerspink HJL
    Nephrol Dial Transplant; 2019 Oct; 34(10):1699-1706. PubMed ID: 30184238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
    Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
    Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    J Am Coll Cardiol; 2011 Jan; 57(1):63-9. PubMed ID: 21185503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Density Lipoprotein Cholesterol Concentration and Acute Kidney Injury After Cardiac Surgery.
    Smith LE; Smith DK; Blume JD; Linton MF; Billings FT
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29223955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).
    Shepherd J; Breazna A; Deedwania PC; LaRosa JC; Wenger NK; Messig M; Wilson DJ;
    Am J Cardiol; 2016 Apr; 117(8):1199-205. PubMed ID: 26940556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.
    Ronsein GE; Hutchins PM; Isquith D; Vaisar T; Zhao XQ; Heinecke JW
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):404-11. PubMed ID: 26681752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impacts of estimated glomerular filtration rate on coronary atherosclerosis and plaque composition before and during statin therapy in patients with normal to mild renal dysfunction: subanalysis of the TRUTH study.
    Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Hibi K; Terashima M; Michishita I;
    Nephrology (Carlton); 2012 Sep; 17(7):628-35. PubMed ID: 22708952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pitavastatin and atorvastatin on regression of atherosclerosis assessed using intravascular ultrasound: a meta-analysis.
    Liu H; Zhang M; Li D; Tian J; Wang X; Pan J; Liu D; Li X; An F
    Coron Artery Dis; 2018 Sep; 29(6):459-468. PubMed ID: 29738341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of change in high-density lipoprotein cholesterol by statin switching on glucose metabolism and renal function in hypercholesterolemia.
    Kakuda H; Matoba M; Nakatoh H; Nagao S; Takekoshi N
    J Clin Lipidol; 2015; 9(5):709-15. PubMed ID: 26350819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.